Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial.

ABSTRACT:

Purpose

Remimazolam is a novel and ultra-short-acting sedative currently developed for intravenous use in procedural sedation, general anesthesia, and ICU sedation. However, intravenous administration is not always appropriate, depending on the patient or setting. This study evaluated intranasal administration as a potential alternative route.

Methods

The study used a randomized, double-blind, 9 period cross-over design to compare the pharmacokinetics, pharmacodynamics, and safety of single intranasal doses of 10, 20, and 40 mg remimazolam (as powder or solution) with intranasal placebo and 4 mg intravenous remimazolam.

Results

Intranasal remimazolam powder had a consistent absolute bioavailability of approximately 50%; T_max was 10 min; AUC and C_max

SUBMITTER: Pesic M 

PROVIDER: S-EPMC7557484 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature